Kaitlyn Kelly, MD, MAS
- Division of Surgical Oncology
- MD, New York Medical College, Valhalla, NY, 2004
- General Surgery Residency, University of Wisconsin Hospital and Clinics, Madison, WI, 2011
- Research Fellowship, Memorial Sloan Kettering Cancer Center, New York, NY, 2008
- Clinical Fellowship, Memorial Sloan Kettering Cancer Center, New York, NY, 2013
- MAS, University of California San Diego, San Diego, CA, 2019
Dr. Kelly’s primary clinical practice includes the treatment of upper gastrointestinal malignancies, including gastric, pancreatic, and hepatobiliary cancers, as well as peritoneal surface malignancy, melanoma, and sarcoma. She is particularly interested in developing minimally invasive techniques for cancer surgery. Dr. Kelly’s primary clinical and research interest is gastric cancer. She is among the highest-volume gastric cancer surgeons in the country with over 10 year of experience, and has pioneered minimally-invasive surgical techniques for gastrectomy with comprehensive lymph node removal. Dr. Kelly also performs some operations with an open technique when necessary, and can perform additional procedures to treat liver cysts, chronic pancreatitis, and gallbladder disease. Dr. Kelly is board-certified in Complex General Surgical Oncology and General Surgery.
Dr. Kelly provides a wide range of services including Laparoscopic and Robotic Gastrectomy, Liver Resection, Laparoscopic Pancreatectomy, Small Bowel and Large Bowel/Colon Resection, Laparoscopic Adrenalectomy, Cytoreductive Surgery with HIPEC, Whipple Procedure, Bile Duct Resection, Cholecystectomy (Gallbladder Removal), Melanoma Wide Local Excision and Skin Closure, Sentinel Lymph Node Biopsy.
Dr. Kelly is a clinical and translational researcher. She is a Nationally-recognized expert in gastric cancer treatment and much of her research is aimed to improve the quality of gastric cancer surgery as it is performed across the U.S. She is also involved in the development and conduct of clinical trials. Dr. Kelly is an active member of the Alliance for Clinical Trials in Oncology, the Eastern Cooperative Oncology Group (ECOG), the American College of Surgeons, the Society of Surgical Oncology, and the American Society of Clinical Oncology.
Culture and Imaging of Ex Vivo Organotypic Pseudomyxoma Peritonei Tumor Slices from Resected Human Tumor Specimens.
Weitz J, Montecillo Gulay KC, Hurtado de Mendoza T, Tiriac H, Baumgartner J, Kelly K, Veerapong J, Lowy AM
J Vis Exp 2022 Dec 09;
[PubMed ID: 36571414]
Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a prospective clinical trial and comparative analysis.
Cho CY, Veerapong J, Baumgartner JM, Murphy JD, Lowy AM, Kelly KJ
Surg Endosc 2023 Jul; 37(7): 5644-5651
[PubMed ID: 36477643]
Use of fluorescence imaging and indocyanine green for sentinel node mapping during gastric cancer surgery: Results of an intercontinental Delphi survey.
Sherwinter DA, Boni L, Bouvet M, Ferri L, Hyung WJ, Ishizawa T, Kaleya RN, Kelly K, Kokudo N, Lanzarini E, Luyer MDP, Mitsumori N, Mueller C, Park DJ, Ribero D, Rosati R, Ruurda JP, Sosef M, Schneider-Koraith S, Spinoglio G, Strong V, Takahashi N, Takeuchi H, Wijnhoven BPL, Yang HK, Dip F, Lo Menzo E, White KP, Rosenthal RJ
Surgery 2022 Dec; 172(6S): S29-S37
[PubMed ID: 36427927]
ASO Visual Abstract: Is Routine Omentectomy a Necessary Component of Cytoreductive Surgery and HIPEC?
Khan S, Doan NH, Hosseini M, Kelly K, Veerapong J, Lowy AM, Baumgartner J
Ann Surg Oncol 2023 Feb; 30(2): 776
[PubMed ID: 36369408]
ASO Author Reflections: A Change Package as a Dissemination Tool for Gastric Cancer Care.
Ann Surg Oncol 2023 Feb; 30(2): 1130-1131
[PubMed ID: 36310310]